Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors
The purpose of these studies was to prepare and characterize nanoparticles into which Coenzyme Q10 (CoQ10) had been incorporated (CoQ10-NPs) using a simple and potentially scalable method. CoQ10-NPs were prepared by cooling warm microemulsion precursors composed of emulsifying wax, CoQ10, Brij 78, and/or Tween 20. The nanoparticles were lyophilized, and the stability of CoQ10-NPs in both lyophilized form and aqueous suspension was monitored over 7 days. The release of CoQ10 from the nanoparticles was investigated at 37°C. Finally, an in vitro study of the uptake of CoQ10-NPs by mouse macrophage, J774A.1, was completed. The incorporation efficiency of CoQ10 was approximately 74%±5%. Differential Scanning Calorimetry (DSC) showed that the nanoparticle was not a physical mixture of its individual components. The size of the nanoparticles increased over time if stored in aqueous suspension. However, enhanced stability was observed when the nanoparticles were stored at 4°C. Storage in lyophilized form demonstrated the highest stability. The in vitro release profile of CoQ10 from the nanoparticles showed an initial period of rapid release in the first 9 hours followed by a period of slower and extended release. The uptake of CoQ10-NPs by the J774A.1 cells was over 4-fold higher than that of the CoQ10-free nanoparticles (P<.05). In conclusion, CoQ10-NPs with potential application for oral CoQ10 delivery were engineered readily from microemulsion precursors.
KeywordsCoenzyme Q10 nanoparticles microemulsion stability cell uptake
Unable to display preview. Download preview PDF.
- 2.Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquin one). Clin Investig. 1993;71(suppl 8):S116-S123.Google Scholar
- 3.Casey AC, Bliznakov EG. Effect and structure-activity relationship of coenzymes Q on the phagocytic rate of rats. Chem Biol Interact. 1972;16:1504–1510.Google Scholar
- 5.Greenberg S, Frishman WH. Coenzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990;30:590–608.Google Scholar
- 6.Kishi H, Kanamori N, Niraoka E, Okamato T, Kishi T. Metabolism of exogenous coenzyme Q10 in vivo and bioavailability of coenzyme Q10 preparations in Japan. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam: Elsevier Science; 1984: 131–142.Google Scholar
- 9.Lutka A, Pawlaczyk J. Inclusion complexation of coenzyme Q10 with cyclodextrins. Acta Pol Pharm. 1995;52:379–386.Google Scholar
- 22.Hsu C-H, Cui Z, Jay M. Nanoparticles engineered from microemulsion precursors for coenzyme Q10 (CoQ10) delivery: preparation and characterization [abstract]. AAPS Pharm Sci. 2002;4(4):W5120.Google Scholar
- 24.Nazzal S, Zaghloul AA, Reddy IK, Khan MA. Analysis of ubidecarenone (CoQ10) aqueous simple using reversed phase liquid chromatography. Pharmazie. 2001;56:394–396.Google Scholar
- 26.Martin A, Swarbrick J, Cammarata A. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. 3rd ed. Philadelphia, PA: Lea & Febiger, 1983:452–454.Google Scholar
- 30.Ford AW, Dawson PJ. The effect of carbohydrate additives in the freeze-drying of alkaline phosphatase. J Pharm Pharmacol. 1993;45:86–93.Google Scholar
- 32.Saiki I, Tokushima Y, Nishimura K, Azuma I. Macrophage activation with ubiquinones and their related compounds in mice. Int J Vitam Nutr Res. 1983;53:312–320.Google Scholar